HHS' Biomedical Advanced Research and Development Authority awarded a four-year contract worth $354 million to Virginia-based Phlow to manufacture medicines and active pharmaceutical ingredients needed to combat COVID-19 as part of the administration's effort to reduce the country's reliance on foreign manufacturing. The contract can be extended for up to $812 million over 10 years.
White House taps Va. firm to manufacture COVID-19 drugs
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.